Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
LUMOS PHARMA, INC.: Certificate of incorporation amended and restated in its entirety.
- Change
- charter amendment
Exact text from the filing
the Surviving Corporation’s certificate of incorporation was amended and restated in its entirety, as set forth on Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
LUMOS PHARMA, INC.: Bylaws of Merger Sub became bylaws of Surviving Corporation.
- Change
- bylaw amendment
Exact text from the filing
the bylaws of Merger Sub as in effect immediately prior to the Effective Time became the bylaws of the Surviving Corporation, as set forth on Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
LUMOS PHARMA, INC. underwent a change of control involving DPV Parent, Inc. for $4.25 per Share in cash plus one non-transferable contingent value right per Share (closed 2024-12-12).
- Action
- change of control
- Counterparty
- DPV Parent, Inc.
- Consideration
- $4.25 per Share in cash plus one non-transferable contingent value right per Share
- Closing
- 2024-12-12
Exact text from the filing
2024, Merger Sub completed a tender offer to purchase all of the issued and outstanding shares of the Company’s common stock, par value $0.01 per share (the “ Shares ”), for (i) $4.25 per Share in cash, without interest and less applicable tax withholding (the “ Cash Amount ”), plus (ii) one non-transferable, unsecured contingent value right per Share, which
View on SEC.gov